THE FADE
REPORT.

Hydroquinone reviews.
The details deserve daylight.

Trace the detail

The source
register.

Provider pages establish what is advertised. FDA, AAD and product labels answer different questions. Every entry was checked September 26, 2026.

Provider

CoreAge Rx: Spot On ↗

Current PDP names hydroquinone, kojic acid and niacinamide; check distinct sales-page source for 6%/6% marketing and conflicting plan prices. Claims do not establish finished-product outcomes.

Provider

Wisp: Brighten Up! ↗

Price, bottle size and ingredients, including expanded Medication Details.

Provider

Wisp: hydroquinone treatment information ↗

One-time reorders and product-specific treatment cautions.

Provider

Nurx: hydroquinone cream ↗

4% cream, supply period, medicine amount and support fee.

Provider

Nurx: melasma treatment costs ↗

Melasma consultation and medication billing.

Provider

Nurx: service costs ↗

Annual melasma consultation and fee in order-processing months.

Provider

RedBox Rx: hydroquinone cream ↗

28.35 g 4% cream, quarterly billing and the provider approval claim.

Provider

RedBox Rx: questions and fees ↗

Handling charge, pharmacy choices and refill arrangements.

Primary guidance

FDA: skin product safety ↗

Hydroquinone and mercury safety concerns.

Primary guidance

FDA: hydroquinone product notice ↗

2022 notice on OTC products and the specific approved Tri-Luma medicine.

Primary guidance

FDA: National Drug Code Directory ↗

A directory listing or NDC is not evidence of approval.

Product label

DailyMed: example single-ingredient 4% label ↗

Example labeled unapproved drug other; not identified as any reviewed provider’s actual supply.

Product label

DailyMed: Tri-Luma label ↗

Specific triple combination, indication and limitations.

Primary guidance

FDA: compounded drug risks ↗

Compounded preparations are not FDA approved.

Primary guidance

FDA: find a state-licensed pharmacy ↗

Check the dispensing pharmacy with the state licensing board.

Primary guidance

AAD: melasma treatment ↗

Diagnosis, clinician-directed treatments and sun protection.

Primary guidance

AAD: fading dark spots ↗

Causes of discoloration and irritation-aware care.

Primary guidance

AAD: skin care during pregnancy ↗

Ingredients to avoid during pregnancy, including hydroquinone.

Provider

Musely: The Spot Cream ↗

Current monthly presentation, two-month supply, auto-refill and provider-reported results; no independent product trial.

Provider

Musely: Spot Cream formula options ↗

Erase, M+, Nurture and HQ Free listings; prescriber changes possible. Provider pregnancy/nursing claim is not adopted as independent evidence.

Provider

Musely: 60-day result guarantee ↗

Initial medication-cost refund conditions, exclusions and nonrefundable doctor-fee language; current checkout not verified.

Provider

Obagi: Clear Fx skin brightening cream ↗

Retail ingredients, $125 regular price, storage and AHA warning. Reviewed ingredient list does not list hydroquinone; arbutin concentration not verified.

Provider

Obagi: prescription product information ↗

Separate prescription Nu-Derm Clear 4% hydroquinone information. Not proof of Clear Fx equivalence or an FDA approval record.

Primary guidance

FDA: hydroquinone and mercury skin-product warning ↗

Adverse-event reports and tested products. No contamination inference about the providers reviewed here.

Primary guidance

FDA: expiration dates and medicine storage ↗

General expiration and storage guidance, not product-specific stability or a cream-color threshold.

Primary guidance

LactMed: hydroquinone during breastfeeding ↗

Revised March 15, 2026. No published maternal or infant levels identified; limited breastfeeding evidence and infant-contact precautions.

Provider

Skin Medicinals: melasma and hyperpigmentation ↗

Lists hydroquinone 4%, 8% and 12%, kojic acid and vitamin C as options; $48+ beside 4% and estimated retail $120+. Not a verified complete patient formula, package quantity, supply period or final order.

Provider

Skin Medicinals: physician and patient workflow ↗

Describes office evaluation, clinician-selected ingredients and subsequent billing/shipping contact. Does not establish immediate telehealth access or independently verified insurance savings.

Clinical

AAD: patch testing for a recurring rash ↗

Explains medical patch testing for suspected allergic contact dermatitis; not a home test, challenge or restart procedure for a prescription cream.

Clinical

NIH NCATS: endpoint definition ↗

Defines the role of primary, secondary and exploratory endpoints. An outcome must remain attached to the study design and product.

Regulatory

FDA: clinical research in drug development ↗

Clinical research context and defined study questions. Does not extend approval or trial outcomes to an untested compounded preparation.

Provider

CoreAge Rx: current Spot On plans ↗

Plan cards advertise hydroquinone 6% and kojic 6%; niacinamide strength unspecified. $165/three months ($54.99 monthly display) and $70/one ($69.99 display); own product-information block conflicts at from $42/month. Provider claims, not checkout or exact-formula trial.

Provider

Obagi: prescription Nu-Derm Clear ↗

Visible product is a cream despite serum in URL; 4% hydroquinone, full inactive list and prescription/physician pathway. Current list differs from March 2018 label. No current price or inventory verified.

Provider

Obagi: Nu-Derm collection ↗

Prescription collection with separate nonprescription bestseller cards; $125 Clear Fx is not a prescription Clear quote.

Drug label

DailyMed: Obagi Nu-Derm Clear, Blender and Sunfader labeling ↗

Revised March 2018. Includes explicit unapproved-drug disclaimer. Historical 57 g Clear package and inactive list; not current stock or proof of current formula. Separate products must not be conflated.

Drug label

Israel Ministry of Health: Esomed Gel patient leaflet ↗

September 2020 patient leaflet for 4% hydroquinone gel. Describes peroxide interaction and temporary color from oxidation. Foreign product record, not US approval, a frequency estimate, diagnosis or instructions for another cream.

Drug label

DailyMed: Marlex hydroquinone 4% cream ↗

Record updated November 13, 2025; unapproved drug other. Used for ochronosis/hypersensitivity warnings, not peroxide interaction, approval or identification of any reviewed service’s supply.

Provider

Likeness Rx — Dark Spot Cream ↗

Official product ingredients, displayed prices and subscription renewal, checked October 4, 2026. No patient care or fulfillment test performed.

Provider shipping reference and supplied service information

CoreAge Rx: shipping and service information ↗

Homepage shipping reference; customer service and payment details supplied for this review, without a checkout or timed support test

Official product or purchase terms

Vinoperfect Facial Radiance Dark Spot Serum | CAUDALIE® ↗

Public source checked for this editorial review; no product-use or transaction test.

Official product or purchase terms

Frequently Asked Questions | CAUDALIE® | RETURN POLICY ↗

Public source checked for this editorial review; no product-use or transaction test.

Clinical background

How to test skin care products ↗

Public source checked for this editorial review; no product-use or transaction test.

Official product or purchase terms

Vitamin illuminating Serum_Original – EQQUALBERRY ↗

Public source checked for this editorial review; no product-use or transaction test.

Official product or purchase terms

Refund policy – EQQUALBERRY ↗

Public source checked for this editorial review; no product-use or transaction test.

Official product or purchase terms

Refund policy – Obagi ↗

Public source checked for this editorial review; no product-use or transaction test.

Scientific evidence

Efficacy and Safety of Generic Fluocinolone Acetonide, Hydroquinone, and Tretinoin Cream Compared With TRI-LUMA for the Treatment of Moderate-To-Severe Melasma in Chinese Patients: A Randomized, Single-Center, Placebo-Controlled Trial. ↗

Full research article, with indexed abstract where available

Scientific evidence

Comparison of Visible Light-Protective Tinted Sunscreen to Untinted Sunscreen to Protect Melasma Patients During Summer: A Prospective Randomized Investigator-Blinded Study. ↗

Full primary research letter plus verified PMC funding footnote; supporting-information document and figure-derived numerical data not reviewed